Trial Profile
A Prospective, Open-Label, Single Arm, Observational Study Assessing Changes in HbA1c, Insulin Dose and Incidence of Hypoglycemia in Patients with Type 1 Diabetes after Switching to Insulin Degludec (IDeg) in Real World Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2016 Results assessing efficacy and cost-effectiveness, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 03 May 2016 New trial record